Eli Lilly's Next-Gen Obesity Drug Trial Success
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 hour ago
0mins
Source: CNBC
- Clinical Trial Success: Eli Lilly's next-generation obesity drug retatrutide successfully cleared its late-stage trial in Type 2 diabetes patients, achieving an average hemoglobin A1c reduction of 1.7% to 2% over 40 weeks, significantly improving blood sugar control and meeting the study's primary endpoint.
- Significant Weight Loss: At the highest dose, patients lost an average of 16.8% of their weight (approximately 36.6 pounds), and even when including those who discontinued treatment, the drug still facilitated a 15.3% weight loss, which is crucial for Type 2 diabetes patients who historically struggle with weight management.
- Low Discontinuation Rates: The trial reported a low discontinuation rate of only 5% due to side effects, indicating that retatrutide's safety profile is comparable to existing injectable diabetes medications, primarily causing mild gastrointestinal reactions, thereby enhancing its competitive edge in the market.
- Broad Market Potential: Lilly expects to report findings from seven additional phase three trials by year-end, positioning retatrutide as the next pillar of its obesity portfolio, potentially leading to direct competition with Novo Nordisk's rival drugs in the market.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy LLY?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on LLY
Wall Street analysts forecast LLY stock price to rise
20 Analyst Rating
18 Buy
2 Hold
0 Sell
Strong Buy
Current: 930.350
Low
950.00
Averages
1192
High
1500
Current: 930.350
Low
950.00
Averages
1192
High
1500
About LLY
Eli Lilly and Company is a medicine company, which discovers, develops, manufactures, markets, and sells pharmaceutical products worldwide. Its cardiometabolic health products include Basaglar; Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, and others; Humulin, Humulin 70/30, and others; Jardiance; Mounjaro; Trulicity; Zepbound; VERVE-102; VERVE-201, and VERVE-301. Its oncology products include Cyramza, Erbitux, Tyvyt, and Verzenio. Its immunology products include Ebglyss, Olumiant, Omvoh, and Taltz. Its neuroscience products include Emgality and Kisunla. The Company is also engaged in radiopharmaceutical discovery, development, and manufacturing efforts, and clinical and pre-clinical radioligand therapies in development for the treatment of cancer. It is also developing an oral small molecule inhibitor of a4b7 integrin for inflammatory bowel disease (IBD). It is evaluating its novel gene therapy candidate, ixoberogene soroparvovec.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Eli Lilly Reports Positive Results for Retatrutide in Type 2 Diabetes Trial
- Clinical Trial Results: In the TRANSCEND-T2D-1 trial, participants using retatrutide achieved average A1C reductions of 1.7% to 2.0% over 40 weeks, demonstrating significant potential for improving glycemic control in diabetes patients, which could transform treatment protocols.
- Weight Loss Impact: Participants on the 12 mg dose lost an average of 36.6 lbs (approximately 16.8%), with this sustained weight loss trend indicating retatrutide's effectiveness in weight management, potentially attracting more patients to clinical trials.
- Safety Assessment: While some adverse events were reported, such as nausea (up to 26.5%) and diarrhea (up to 26.3%), these primarily occurred during dose escalation and were mostly mild, suggesting that the drug's safety profile remains within acceptable limits.
- Future Outlook: Detailed results from TRANSCEND-T2D-1 will be presented at the American Diabetes Association Scientific Sessions in June, and Eli Lilly plans to release more clinical trial results on retatrutide over the next year, further validating its therapeutic potential in diabetes treatment.
See More
Eli Lilly's Next-Gen Weight Loss Therapy Achieves Key Trial Success
- Trial Success: Eli Lilly announced that its next-generation weight loss therapy, retatrutide, successfully met primary and all secondary endpoints in the TRANSCEND-T2D-1 trial for type 2 diabetes patients, demonstrating an average A1C reduction of 2.0% over 40 weeks.
- Significant Weight Loss: Patients receiving retatrutide lost an average of 36.6 lbs, equating to approximately 17% weight loss, indicating the drug's sustained efficacy throughout the trial, which may attract more patients seeking weight loss solutions.
- Safety Profile: While adverse events were similar to those seen in other incretin-based therapies, dropout rates due to adverse events for retatrutide were 2.2%, 4.5%, and 5.1% for the 4 mg, 9 mg, and 12 mg doses respectively, highlighting safety concerns compared to the placebo group.
- Future Data Release: Eli Lilly plans to release additional data from TRANSCEND-T2D next year and present detailed results at a medical event, indicating the company's confidence in the therapy and its potential impact on the weight loss market.
See More
Eli Lilly Reports Strong Phase 3 Results for Diabetes Drug Retatrutide
- Successful Clinical Trial: Eli Lilly's experimental drug retatrutide met all key endpoints in the TRANSCEND-T2D-1 trial, demonstrating better blood sugar control and weight loss compared to placebo, with A1C levels dropping by up to 2% after 40 weeks.
- Significant Weight Loss: Patients experienced an average weight loss of up to 36.6 pounds (approximately 16.8%), with the weight loss effect persisting throughout the treatment period, indicating the drug's effectiveness and tolerability.
- Cardiovascular Risk Improvement: Retatrutide also showed improvements in key cardiovascular risk factors, including cholesterol and blood pressure, further enhancing its potential as a diabetes treatment.
- Mild Side Effects: The most common side effects were mild to moderate gastrointestinal issues such as nausea and diarrhea, indicating good safety profile for long-term use.
See More
Novo Nordisk Faces Challenges but Remains Optimistic
- Market Share Decline: Novo Nordisk is losing ground in the GLP-1 market, with revenue expected to decline by 2026; despite these challenges, investors remain optimistic about the company's future prospects.
- Rich Clinical Experience: With over 100 years in the diabetes drug market, Novo Nordisk has amassed extensive clinical trial data, providing significant advantages in drug development, particularly in the rapidly growing obesity drug sector.
- Strong Manufacturing Capability: The company possesses the infrastructure and expertise to produce GLP-1 drugs at scale, allowing it to meet rising market demand more effectively than many peers, ensuring its competitiveness in the pharmaceutical industry.
- Attractive Valuation Levels: Currently trading at a forward P/E of 10.4, significantly below the healthcare sector average of 17.8, Novo Nordisk's stock appears attractive in the current market environment, making it suitable for long-term holding.
See More
Eli Lilly Reports Positive Phase 3 Results for Diabetes Drug
- Successful Clinical Trial: Eli Lilly's Phase 3 TRANSCEND-T2D-1 study achieved its primary and all key secondary endpoints, demonstrating significant A1C reduction and weight loss compared to placebo.
- Significant A1C Reduction: Participants treated with retatrutide experienced average A1C reductions of up to 2% over 40 weeks, indicating the drug's effectiveness in blood sugar control.
- Weight Loss Impact: Participants lost an average of 36.6 pounds (16.8%), with weight loss continuing throughout the treatment period, showcasing the drug's long-term efficacy.
- Market Reaction: Despite the positive trial results, Eli Lilly's shares closed down 1.32% at $918.05, reflecting market caution regarding the drug's future commercialization prospects.
See More
Novo Nordisk Faces Challenges but Remains Optimistic
- Market Leadership: Novo Nordisk has a century-long history in the diabetes drug market, leveraging extensive clinical trial data and successes to quickly establish leadership in the obesity drug market, thereby enhancing its competitive position.
- Manufacturing Capability: The company possesses a robust manufacturing infrastructure that meets the specific demands of GLP-1 drug production, ensuring it can maintain supply in a rapidly growing market, thus increasing its market share.
- Brand Trust: Novo Nordisk's brand is highly trusted among physicians and patients, which will accelerate the commercialization of its new medicines, helping the company secure a favorable position in future market competition.
- Valuation Appeal: Currently, Novo Nordisk's forward P/E ratio stands at 10.4, significantly lower than the healthcare sector average of 17.8, indicating the stock's investment attractiveness and suitability for long-term holding to capture future growth potential.
See More
Eli Lilly Reports Positive Results for Retatrutide in Type 2 Diabetes Trial
- Clinical Trial Results: In the TRANSCEND-T2D-1 trial, participants using retatrutide achieved average A1C reductions of 1.7% to 2.0% over 40 weeks, demonstrating significant potential for improving glycemic control in diabetes patients, which could transform treatment protocols.
- Weight Loss Impact: Participants on the 12 mg dose lost an average of 36.6 lbs (approximately 16.8%), with this sustained weight loss trend indicating retatrutide's effectiveness in weight management, potentially attracting more patients to clinical trials.
- Safety Assessment: While some adverse events were reported, such as nausea (up to 26.5%) and diarrhea (up to 26.3%), these primarily occurred during dose escalation and were mostly mild, suggesting that the drug's safety profile remains within acceptable limits.
- Future Outlook: Detailed results from TRANSCEND-T2D-1 will be presented at the American Diabetes Association Scientific Sessions in June, and Eli Lilly plans to release more clinical trial results on retatrutide over the next year, further validating its therapeutic potential in diabetes treatment.
See More
Eli Lilly's Next-Gen Weight Loss Therapy Achieves Key Trial Success
- Trial Success: Eli Lilly announced that its next-generation weight loss therapy, retatrutide, successfully met primary and all secondary endpoints in the TRANSCEND-T2D-1 trial for type 2 diabetes patients, demonstrating an average A1C reduction of 2.0% over 40 weeks.
- Significant Weight Loss: Patients receiving retatrutide lost an average of 36.6 lbs, equating to approximately 17% weight loss, indicating the drug's sustained efficacy throughout the trial, which may attract more patients seeking weight loss solutions.
- Safety Profile: While adverse events were similar to those seen in other incretin-based therapies, dropout rates due to adverse events for retatrutide were 2.2%, 4.5%, and 5.1% for the 4 mg, 9 mg, and 12 mg doses respectively, highlighting safety concerns compared to the placebo group.
- Future Data Release: Eli Lilly plans to release additional data from TRANSCEND-T2D next year and present detailed results at a medical event, indicating the company's confidence in the therapy and its potential impact on the weight loss market.
See More
Eli Lilly Reports Strong Phase 3 Results for Diabetes Drug Retatrutide
- Successful Clinical Trial: Eli Lilly's experimental drug retatrutide met all key endpoints in the TRANSCEND-T2D-1 trial, demonstrating better blood sugar control and weight loss compared to placebo, with A1C levels dropping by up to 2% after 40 weeks.
- Significant Weight Loss: Patients experienced an average weight loss of up to 36.6 pounds (approximately 16.8%), with the weight loss effect persisting throughout the treatment period, indicating the drug's effectiveness and tolerability.
- Cardiovascular Risk Improvement: Retatrutide also showed improvements in key cardiovascular risk factors, including cholesterol and blood pressure, further enhancing its potential as a diabetes treatment.
- Mild Side Effects: The most common side effects were mild to moderate gastrointestinal issues such as nausea and diarrhea, indicating good safety profile for long-term use.
See More
Novo Nordisk Faces Challenges but Remains Optimistic
- Market Share Decline: Novo Nordisk is losing ground in the GLP-1 market, with revenue expected to decline by 2026; despite these challenges, investors remain optimistic about the company's future prospects.
- Rich Clinical Experience: With over 100 years in the diabetes drug market, Novo Nordisk has amassed extensive clinical trial data, providing significant advantages in drug development, particularly in the rapidly growing obesity drug sector.
- Strong Manufacturing Capability: The company possesses the infrastructure and expertise to produce GLP-1 drugs at scale, allowing it to meet rising market demand more effectively than many peers, ensuring its competitiveness in the pharmaceutical industry.
- Attractive Valuation Levels: Currently trading at a forward P/E of 10.4, significantly below the healthcare sector average of 17.8, Novo Nordisk's stock appears attractive in the current market environment, making it suitable for long-term holding.
See More
Eli Lilly Reports Positive Phase 3 Results for Diabetes Drug
- Successful Clinical Trial: Eli Lilly's Phase 3 TRANSCEND-T2D-1 study achieved its primary and all key secondary endpoints, demonstrating significant A1C reduction and weight loss compared to placebo.
- Significant A1C Reduction: Participants treated with retatrutide experienced average A1C reductions of up to 2% over 40 weeks, indicating the drug's effectiveness in blood sugar control.
- Weight Loss Impact: Participants lost an average of 36.6 pounds (16.8%), with weight loss continuing throughout the treatment period, showcasing the drug's long-term efficacy.
- Market Reaction: Despite the positive trial results, Eli Lilly's shares closed down 1.32% at $918.05, reflecting market caution regarding the drug's future commercialization prospects.
See More
Novo Nordisk Faces Challenges but Remains Optimistic
- Market Leadership: Novo Nordisk has a century-long history in the diabetes drug market, leveraging extensive clinical trial data and successes to quickly establish leadership in the obesity drug market, thereby enhancing its competitive position.
- Manufacturing Capability: The company possesses a robust manufacturing infrastructure that meets the specific demands of GLP-1 drug production, ensuring it can maintain supply in a rapidly growing market, thus increasing its market share.
- Brand Trust: Novo Nordisk's brand is highly trusted among physicians and patients, which will accelerate the commercialization of its new medicines, helping the company secure a favorable position in future market competition.
- Valuation Appeal: Currently, Novo Nordisk's forward P/E ratio stands at 10.4, significantly lower than the healthcare sector average of 17.8, indicating the stock's investment attractiveness and suitability for long-term holding to capture future growth potential.
See More
